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SynergismAbstract Introduction: Pseudomonas aeruginosa (P. aeruginosa) is a highly resistant opportunistic
pathogen and is capable of forming bioﬁlms on medical devices. Bacterial bioﬁlms, which are
micro-colonies encased in extracellular polysaccharide material are so difﬁcult to be treated by con-
ventional antibiotics. During the last decade, P. aeruginosa phages have been extensively examined
as an alternative to antimicrobial agents. The aim of the study was to assess bacteriophage-
antibiotic combination on planktonic and bioﬁlm states of P. aeruginosa isolates.
Materials: In this study, we isolated 6 lytic phages, from hospital efﬂuents, they were tested against
50 P. aeruginosa strains, isolated from different clinical specimens delivered to the Diagnostic
Microbiology Laboratories, Faculty of Medicine, Alexandria University.
Results: Out of the 50 isolates, 15 were susceptible to these phages. So the bioﬁlm forming capacity
of these 15 isolates was investigated. The results showed that 14 isolates (93.33%) produced detect-
able bioﬁlm. The minimum inhibitory concentration (MIC) and minimum bioﬁlm eradication con-
centration (MBEC) assays were used to evaluate the antibiotic sensitivity patterns of these P.
aeruginosa isolates in their planktonic and bioﬁlm phases to amikacin and meropenem. Also, the
effects of phage on the planktonic and bioﬁlm states of isolates at different multiplicities of infec-
tions (MOI) were tested. On the planktonic state, the amikacin-phage combination showed syner-
gistic effect (P= 0.001), and the meropenem-phage combination showed synergistic effect
(P= 0.003). On the bioﬁlm state, the amikacin-phage combination showed bioﬁlm eradicationoo.com
100 A.A.M. Nouraldin et al.in 50% of the isolates (P= 0.003). On the other hand, the meropenem-phage combination showed
bioﬁlm eradication in 14.3% of the strains.
Conclusion: The combination of phage and antibiotics could have potentially more beneﬁts on P.
aeruginosa planktonic and bioﬁlm states than just using phages or antibiotics alone.
Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pseudomonas aeruginosa (P. aeruginosa) is one of the leading
causes of nosocomial infections, being responsible for high
rates of mortality and morbidity.1 This bacterium is the most
frequently isolated Gram-negative organism in bloodstream,
wound infections, pneumonia, intra-abdominal and urogenital
sepsis. This is a serious problem, also infecting immunocom-
promised patients with cystic ﬁbrosis, severe burns, cancer,
AIDS, etc.2
One of the most worrying characteristics of this bacterium
is its low antibiotic susceptibility. Overuse of antibiotics has
also signiﬁcantly increased the emergence of antimicrobial
multidrug-resistant bacteria; consequently, treatment of most
chronic P. aeruginosa infections with antibiotics is difﬁcult.
Additionally, P. aeruginosa has an innate ability to adhere to
surfaces and form virulent bioﬁlms particularly difﬁcult to
eradicate.3
It is well recognized that bioﬁlm mode of growth can pro-
mote resistance to antimicrobial agents, and its occurrence
during the infectious process has been considered a limiting
factor for therapeutic success.1
Bioﬁlm is a structured community of bacterial cells adher-
ent to an inert or living surface and/or embedded in a self-
produced extracellular polymeric substances’ (EPS) matrix.
The bacteria within the bioﬁlms are protected from physical,
chemical and biological stresses, including antimicrobial
agents, antibodies and the antimicrobial products of phago-
cytic cells.4 The mechanism of bioﬁlm resistance is multifac-
torial. Treatment with antibiotics may kill planktonic
bacteria (free living bacteria) shed from the bioﬁlm surface;
however, they fail to eradicate those embedded within the
bioﬁlm, which can then subsequently act as a nidus for recur-
rent infection.5
So, new alternative strategies to antibiotherapy are highly
needed by the worldwide medical and scientiﬁc community.
Bacteriophages (phages) are considered the natural enemies
of bacteria and may represent an attractive solution to this
problem.6
Phage therapy is based on the use of lytic phages to combat
bacterial infections, including multidrug-resistant bacteria and
has many advantages compared to antibiotics: they persist as
long as the targeted bacteria are present, they are very speciﬁc
and efﬁcient for their target bacteria, which reduce destruction
of the host’s natural ﬂora; and they are not pathogenic for
human.7
The aim of this study was to assess bacteriophage-
antibiotic (amikacin/meropenem) synergism to control plank-
tonic and bioﬁlm states of clinical isolates of P. aeruginosa by
determining their MICs (minimum inhibitory concentrations)
and MBECs (minimum bioﬁlm eradicating concentrations)
values.2. Material and methods
2.1. Bacterial strains
The material of this study consisted of 50 strains of P. aerug-
inosa isolated from various clinical specimens processed in the
Microbiology Laboratory, Faculty of Medicine, Alexandria
Main University Hospital, over a period of time from June
through September 2013.
2.2. Identiﬁcation of strains
Colonies of P. aeruginosa on blood agar were identiﬁed
according to the standard microbiological techniques.8
2.3. Isolation of Bacteriophages:2,9
Phages were isolated from Alexandria University Hospital
efﬂuents during the same period of collection of the study
strains. These efﬂuents were enriched with different isolated
P. aeruginosa strains in double strength Tryptone Soya
Broth (TSB) medium (Oxoid, UK). This solution was incu-
bated for 48 h, then centrifuged for 10 min at 2500 rpm to col-
lect the supernatant. The supernatant was ﬁltered through a
0.45-lm membrane ﬁlter. This supernatant was then checked
for the presence of lytic phages by spotting 10 ll onto lawns
of different P. aeruginosa isolates on Tryptone Soya Agar
(TSA) plates. After overnight incubation, the formation of
clear zones (plaques) suggested the presence of lytic phage
speciﬁc for each strain.9
2.3.1. Titration of bacteriophages by Double Agar Overlay
(Plaque Assay)10
TSA plates were prepared. Three ml of Soft agar (TSB with
0.7% agar) was prepared in sterile tubes. TSB was prepared
and used as a diluent for the bacteriophages (in 1 ml quanti-
ties). One hundred microliters of phage lysate were added to
the ﬁrst tube and serial 10-fold dilutions were made. One hun-
dred microliters of phage lysate from each dilution were added
to 100 ll of overnight grown P. aeruginosa strain in TSB as 0.5
Mcfarland11, speciﬁc to that phage, and mixed with three ml
sterile molten soft agar. This mixture was poured over sterile
TSA plate for each phage dilution. The overlays were left to
harden for 30 min, and then the plates were incubated inverted
at 37 C for 24 h. Plates were checked for plaque formation
and plaque forming units were calculated according to the fol-
lowing equation.9,10
Plaque forming units ðPFUÞ=ml
¼ ðNumber of plaquesÞ  ðDilution FactorÞ
Phage volume plated ðmlÞ
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P. aeruginosa isolates were cultured overnight in TSB. A
volume of 200 ll was transferred to each of three wells of
a sterile 96 wells polystyrene microtiter plate ﬂat bottom
(Becton Dickinson, Franklin Lakes, NJ, USA), so that each
isolate was tested in triplicate. After incubation for 24 h at
37 C, the contents of the wells were discarded and the wells
were gently washed three times with 200 ll sterile phosphate-
buffered-saline (PBS) (pH 7.2). 200 ll of 2% Sodium acetate
solution was added to each well and kept for 5 min (for
bioﬁlm ﬁxation). The plate was then washed using PBS,
followed by addition of 200 ll crystal violet (0.5%) for
30 min at room temperature for bioﬁlm staining. The plate
was then washed with tape water. In each run a negative
control was included (non-bioﬁlm forming P. aeruginosa).
The absorbance (optical density, OD) of the remaining
surface-adsorbed cells of the individual wells was read using
a spectrophotometer (ELX 800 Universal Microplate Reader
Bio-TEC Instruments, INC.) at a wave length of 545 nm.
The optical density cut-off value (ODc) = OD of the nega-
tive control.
OD the isolate 6 ODc was considered absent bioﬁlm, and
OD the isolate between ODc and 2X ODc is considered weak
bioﬁlm. OD the isolate between 2X ODc and 4X ODc is con-
sidered moderate bioﬁlm and OD the isolate > 4X ODc is
considered strong bioﬁlm producing strain.1
2.3.3. MIC determination
Based on studies in Egypt amikacin was the most active drug
against P. aeruginosa followed by meropenem, hence the
choice of theses antibiotics for further testing.
MICs of amikacin (range 0.25–512 mg/L) and meropenem
(range 0.25–512 mg/L) for the P. aeruginosa strains selected
for bioﬁlm studies were determined using cation adjusted
Mueller Hinton broth (CAMHB) (Oxoid, Basingstoke, UK)
according to the CLSI broth microdilution method. Results
were interpreted as follows: for amikacin (Sensitive:
616 lg/ml, Intermediate: 32 lg/ml, Resistant: P64 lg/ml),
for meropenem (Sensitive: 62 lg/mL, Intermediate: 4 lg/ml,
Resistant: P8 lg/mL).12
2.3.4. MBEC determination
A single colony from the selected bioﬁlm producing P. aerug-
inosa isolate was added to a test tube containing 2 ml TSB.
After overnight incubation, the turbidity was adjusted11 and
200 ll of the bacterial suspension was added to wells of the
microtiter plate. These were incubated for 24 h at 37 C aero-
bically. Planktonic cells were removed by washing with PBS.
The remaining attached bacteria were resuspended in 100 lL
of CAMHB and challenged with 100 ll of amikacin at differ-
ent 2 fold dilutions (2–512 lg/ml) or meropenem at different 2
fold dilutions (2–512 lg/ml). Each dilution was tested in tripli-
cate and the plates were incubated for another 24 h at 37 C.
The drug was removed and the wells were rinsed three times
with PBS. The subsequent steps (i.e., ﬁxation and staining)
were performed as in the bioﬁlm formation assay. A positive
control (the bioﬁlm producing strain without adding amikacin
or meropenem) and a negative control (a bioﬁlm negative
strain without adding amikacin or meropenem) were also
included in the experiment, each in its respective well. The
MBEC was deﬁned as the minimum concentration of amikacin(or meropenem) required to eradicate the bioﬁlm. Eradication
of bioﬁlm gave a reading 6 ODc negative control.4,13
Testing the effect of phage on the planktonic cells: Speciﬁc
phages were tested against the speciﬁc Pseudomonas isolates at
different multiplicities of infection(MOI), where MOI is the
average number of virus particles infecting each cell
(MOI = Plaque forming units (PFU) of virus used for
infection/number of cells).14 A 0.5 Mcfarland (1 · 108 cfu/ml)
suspension of P. aeruginosa isolate was prepared in TSB.
One hundred microliters of the suspension were added to
100 ll of phage lysate of concentration 108 PFU/ml (to give
MOI = 1) in a well of the microtiter plate. Plates were incu-
bated for 24 h at 37 C, then examined for clearance of the
wells.13,15
Testing phage on bacterial Bioﬁlm at different MOI (1, 2,
4): Each dilution was tested in triplicates and the plates were
incubated for 24 h at 37 C. The phage was removed and the
wells were rinsed three times with PBS. The subsequent steps
(i.e., ﬁxation and staining) were performed as in the bioﬁlm
formation assay. Eradication of the bioﬁlm gave an OD
reading similar to that of the negative control.16
Antibiotic and phage synergism against the planktonic
cells: MIC method was done as mentioned before, where
100 ll of different concentrations of the Antibiotic
(Amikacin) (ranging from 0.25 to 512 lg/ml) were put in wells
of microtiter plate. One hundred microliters of phage lysate
108 PFU/ml were added to these wells and ﬁnally 100 ml of
bacterial suspension 108 cfu/ml were added to the wells. The
same steps were repeated for the meropenem.17
Antibiotic and phage synergism against the bioﬁlm: After
doing the same bioﬁlm assay, planktonic cells were removed
by washing with PBS leaving only the bioﬁlm bacteria attached
to the microtiter plate. One hundred microliters of antibiotic at
different 2 fold dilutions (2, 4, 8, 16, 32, 64, 128, 256 and
512 lg/ml) and 100 ml Phage 108 PFU/ml (to give
MOI = one), were added to each well, this was applied for
both amikacin and meropenem. Each dilution was tested in
triplicates and the plates were incubated for 24 h at 37 C.
The Antibiotic and the phage were removed and the wells were
rinsed three times with PBS.13,16
2.3.5. Statistical analysis
The data were analyzed using SPSS package version 18. The
following statistical measures were used:
Descriptive statistics including frequency, distribution,
median, and inter quartile range were used to describe different
characteristics. Univariate analyses including the following:
Mann Whitney test and Wilcoxon Signed ranks test were used
to test the signiﬁcance of results of quantitative variables.
Fisher’s Exact test and McNemar test were used to test the sig-
niﬁcance of results of qualitative variables. The signiﬁcance of
the results was at the 5% level of signiﬁcance.
3. Results
Fifty P. aeruginosa strains were isolated. The isolates were
mostly from urine (50%), followed by pus (40%) and (10%)
were from broncho–alveolar lavage.
Six phages were isolated from Alexandria University
Hospital efﬂuents, they were tested against the 50 strains.
Out of the 50 isolates, 15 were susceptible to these phages.
Table 2 The effect of combination of the sub MIC concen-
tration of Amikacin or Meropenem with the corresponding
bacteriophage on Planktonic state of P. aeruginosa strains.
The eﬀect Amikacin-phage
(n= 15)
Meropenem-phage
(n= 15)
No. % No. %
Synergism 13 86.7 11 73.3
No eﬀect 2 13.3 4 26.7
Total 15 100 15 100
Signiﬁcance Z= 3.185
P= 0.001*
Z= 2.944
P= 0.003*
Z: Wilcoxon Signed ranks test.
* Signiﬁcant at P 6 0.05.
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isolated were tested for their ability to form bioﬁlm by micro-
titer plate method (MTP). Fourteen isolates (93.33%) pro-
duced detectable bioﬁlm by MTP. Among these 14 isolates,
eight isolates produced strong bioﬁlm and six isolates pro-
duced moderate/weak bioﬁlm (Table 1).
Determination of amikacin/meropenem MBEC: The 14
bioﬁlm producing isolates (100%) had MBEC for greater than
the deﬁned planktonic MIC breakpoint for resistance (P64)
for amikacin and (P8) for meropenem.
Table 1 shows that amikacin reduced the bioﬁlm in (50%)
of the strong P. aeruginosa bioﬁlm producing isolates and in
(66.7%) of the moderate bioﬁlm producing isolates, yet this
was statistically insigniﬁcant (p= 0.627). Similarly, merope-
nem produced reduction of the bioﬁlm in (25%) of the strong
bioﬁlm producers and in (50%) of the moderate bioﬁlm pro-
ducers, this was also statistically insigniﬁcant (p= 0.58).
By testing the effect of the corresponding phage on plank-
tonic state of P. aeruginosa strains at different MOI, clearance
of the wells was produced in 5 out of 15 isolates (33.3%).
These 5 isolates were susceptible at MOI 4. The remaining
10 isolates (66.6%) needed MOI > 4. As for phage effect on
bioﬁlm, three out of the 14 bioﬁlm producing P. aeruginosa iso-
lates (21.42%) showed bioﬁlm eradication at MOI = 4, two of
these isolates showed this effect by using phage cocktail,
whereas 11 of the isolates (78.57%) needed MOI > 4 to erad-
icate the bioﬁlm.
Testing the effect of combination of the sub MIC concen-
tration of amikacin/meropenem and the corresponding phage
at a MOI = one on the planktonic P. aeruginosa strains
revealed that the amikacin-phage combination produced syn-
ergistic effect on 13 out of 15 strains (86.66%), but had no
effect on the other two strains (13.33%). The meropenem-
phage combination showed synergistic effect on 11 out of the
15 strains (73.33%) and had no effect on the other four strains
(26.67%). Statistically, it was found that the median MIC
value of amikacin alone on P. aeruginosa strains was 64 and
with phage combination it was reduced to 16. Also, the median
MIC value of meropenem alone was 64 and with phage com-
bination it was reduced to 32 (Table 2).
Statistically, Table 2 shows that the antibiotic-phage com-
bination caused considerable great reduction of the MIC forTable 1 Relation between strength of bioﬁlm production in P.
aeruginosa strains and effect of Amikacin and Meropenem on
the bioﬁlm.
Antibiotics Strong
(n= 8)
Moderate/
weak
(n= 6)
Signiﬁcance
No. % No. %
Amikacin
Detected eﬀect on bioﬁlm FEP= 0.627
No reduction 4 50 2 33.3
Reduced to weak 4 50 4 66.7
Meropenem
Detected eﬀect on bioﬁlm FEP= 0.58
No reduction 6 75 3 50
Reduced to weak 2 25 3 50
FEP: Fisher’s Exact test, Z: Mann Whitney test.P. aeruginosa strains in the planktonic state (amikacin
P= 0.001)/(meropenem P= 0.003).
The effect of combination of amikacin (at MIC of 6512)
and the corresponding bacteriophage at MOI = (one) on the
14 bioﬁlm producing P.aeruginosa strains was attempted.
Eradication of the bioﬁlm occurred in 7 out of the 14 strains
(50%). As for meropenem (at MIC 6 512) with phage combi-
nation, eradication of the bioﬁlm occurred in two out of the 14
strains (14.28%) (Table 3).
Statistically, Table 3 shows that the amikacin-phage combi-
nation caused signiﬁcant eradication of P. aeruginosa bioﬁlm
(p= 0.003), whereas the meropenem-phage combination
caused no signiﬁcant eradication of P. aeruginosa bioﬁlm
(p= 0.481).
4. Discussion
P. aeruginosa is a ubiquitous organism which has emerged as a
major threat in hospital environment. It is one of the most
resistant bacterial pathogens. Many medical implants such as
catheters, artiﬁcial hips and contact lenses can easily get colo-
nized by P. aeruginosa.18Table 3 Effect of using Amikacin or Meropenem at different
concentrations with and without combination with the corre-
sponding bacteriophage on eradication of P. aeruginosa
bioﬁlm.
Antibiotic Without
adding the
phage
With adding
the phage
Signiﬁcance
No % No %
Amikacin MNP= 0.003*
Eradication 0 0 7 50
No eradication 14 100 7 50
Meropenem MNP= 0.481
Eradication 0 0 2 14.3
No eradication 14 100 12 85.7
MNP: McNemar test.
* Signiﬁcant at P 6 0.05.
Bacteriophage-antibiotic synergism to control planktonic and bioﬁlm producing clinical isolates of Pseudomonas aeruginosa 103In the present study 25 out of 50 P. aeruginosa strains
(50%) were isolated from urine, (40%) from pus and (10%)
from BAL.
Our study revealed that, only 15 of our isolates had speciﬁc
lytic phages. Fourteen out of these 15 isolates (93.33%) had
the ability to produce bioﬁlm by the MTP. Out of these 14 iso-
lates 8 produced strong bioﬁlm (57.1%) and six produced
moderate/weak bioﬁlm (42.8%).
These results were close to those obtained by Deligiann
et al.19 who studied P. aeruginosa bioﬁlm producing isolates
from sputum samples taken from children with cystic ﬁbrosis.
They found that (47.9%) produced strong bioﬁlm, (19.7%)
produced moderate bioﬁlm and (32.2%) produced weak bio-
ﬁlm. However, those isolated from cystic ﬁbrosis were
expected to have strong bioﬁlm.
A group of Egyptian-Saudi investigators20 conducted a
study on P. aeruginosa MDR strains in 2013. They found that
18 out of 40 strains (45%) produced bioﬁlm. Sixteen (89%) of
these strains were strong bioﬁlm-producers, one strain was
moderate and another one was weak bioﬁlm-producer. These
results might reﬂect the different sources from which the
strains were isolated.
In this study, (42.8%) of the bioﬁlm producing P. aerugi-
nosa isolates were isolated from urine, (42.8%) from pus and
(14.2%) from BAL.
In our study 4 out of 15 (27%) planktonic isolates were sus-
ceptible to amikacin (MIC 6 32 lg/ml) whereas 11 isolates
(73%) were resistant. On the other hand, all the 14 (100%) bio-
ﬁlm producing isolates showed high amikacin MBEC
(P64 lg/ml) and cannot be considered susceptible to amikacin
according to the 2014 CLSI breakpoints.12 This reﬂects the
antibiotics abuse in the community, leading to such high rates
of resistance.
Similar results were obtained when strains were challenged
with meropenem where 3 out of 15 (20%) planktonic isolates
were susceptible to meropenem (MIC 6 2 lg/ml) whereas 12
isolates (80%) were resistant. Similarly, all the 14 (100%) bio-
ﬁlm producing isolates showed high meropenem MBEC
(P8 lg/ml) and cannot be considered susceptible according
to the 2014 CLSI breakpoints.12
However in cases of biomaterial associated infections, in
which bioﬁlm formation is the main characteristic, conven-
tional MIC only predicts the ability of an antimicrobial agent
to inhibit the growth of the bacteria released from the bioﬁlm,
not the bacterial growth within bioﬁlm matrix.21
However, Liu stated that Brown et al.22 found that 20% of
P. aeruginosa were resistant to amikacin in their planktonic
state and 55% of P. aeruginosa isolates were resistant in their
bioﬁlm state. In another study, Saxena et al.23, in India, found
that 31.8% of the bioﬁlm producing P. aeruginosa strains iso-
lated from patients with lower respiratory tract infections were
resistant to amikacin.
The higher resistance of amikacin and meropenem in the
bioﬁlm state more than planktonic state of P. aeruginosa can
be explained by the decreased diffusion of antimicrobial agents
through the extensive bioﬁlm matrix where there is increase in
alginate synthesis in bioﬁlm. Aminoglycoside antibiotics are
clearly less effective against the same micro-organism in anaer-
obic conditions which are provided by the bioﬁlm than in aer-
obic conditions.24 Alternatively, the depletion of a substrate or
accumulation of an inhibitive waste product might cause some
bacteria to enter a non-growing state, in which they areprotected from killing.5 b-lactam antibiotics, which target
cell–wall synthesis, kill only growing bacteria and cannot act
on the metabolically inactive bacteria in the bioﬁlms.25
The development of new alternatives to antibiotherapy for
eradication and control of virulent bioﬁlms from surfaces,
mainly of medical devices, has become a great challenge in
the scientiﬁc community. Several studies have shown the
potential of use of phages to treat infectious diseases in ani-
mals26 and humans27, even those caused by multidrug-
resistant bacteria.28
The 15 strains of the present study were susceptible to 6
lytic phages isolated from efﬂuents isolated from the same hos-
pital over several months.
It is expected that phage action on planktonic cells is more
efﬁcient than in bioﬁlms due to bioﬁlm architecture, which pre-
vents easy access of phages to the bacteria.29 Sillankorva et al.30
studied the effect of phage on P. ﬂuorescens planktonic and
bioﬁlm states. They found that phage infection of planktonic
culture of P. ﬂuorescens resulted in a sharp increase of cell
lysis, whereas the rate of cell lysis in bioﬁlms was signiﬁcantly
lower.
Contrary to that expectation, our study showed low activity
of phage against planktonic cells where 5 out of 15 strains
(33.3%) were susceptible at MOI = 4.
On the other hand, 3 out of the 14 bioﬁlm producing iso-
lates (21.4%) were eradicated by their speciﬁc phages. It is
noteworthy that two of these isolates showed bioﬁlm eradica-
tion by using phage cocktail. Similarly, Pires et al.2 studied the
use of newly isolated phages to control P. aeruginosa PAO1
and ATCC 10145 and found that both planktonic and bioﬁlm
states were resistant to the reference phage PhiIBB-PAP21.
They explained this by that after 9–10 h of infection, plank-
tonic P. aeruginosa PAO1 cell cultures began to grow again.
This ﬁnding can be explained that the interaction of phages
and bacteria during long periods of time can result in the emer-
gence of phage-resistant bacteria and increase bacterial den-
sity.31 However, other authors found that bacterial density
was not observed to increase in vivo, since the combination
of phage and host defences is sufﬁcient to keep the bacterial
density below the lethal threshold after phage therapy.32
Thus, maybe short periods of treatment seem to be a better
solution for avoiding the emergence of phage-resistant hosts.
The use of phage cocktails also, presented advantages over
the use of single phage, since phages can be selected in such
a way to overwhelm host resistance mutations.2
Nevertheless, despite the potential of phages as antimicro-
bial agents, it is well known that bacteria can quickly adapt
and create new survival strategies and the emergence of
phage-resistant phenotypes is inevitable. Thus, the combina-
tion of phage and antibiotic therapies could have potentially
more beneﬁts than just using phages or antibiotics alone.33
The results of the present study demonstrated that the asso-
ciation of phage at MOI = 1 with the sub-MIC values of ami-
kacin on P. aeruginosa strains, in their planktonic state, was
statistically signiﬁcant, where 13 out of 15 (86.66%) strains
showed synergistic effect, whereas two strains (13.33%)
showed no effect by this combination. Moreover, the combina-
tion of Sub MIC of meropenem and the corresponding phage
at MOI = 1 on the 15 P. aeruginosa strains in planktonic state
demonstrated that 11 (73.33%) strains showed synergistic
effect, whereas four (26.67%) showed no effect by this combi-
nation. So the Median dose for amikacin and meropenem has
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aeruginosa in the planktonic state.
Similar to our ﬁndings, Hagens et al.34 studied the combi-
nation of phage and low doses of antibiotics on P. aeruginosa
strains and found that this combination was able to inhibit the
growth or kill P. aeruginosa and that the resistance to tetracy-
cline was drastically reduced upon infection with phage.
These ﬁndings can be explained by two postulations: The
ﬁrst is the fact that the principal barrier to antibiotics in
Gram-negative bacteria is the outer membrane, which in P.
aeruginosa is augmented by the active efﬂux system MexAB-
OprM. However, during ﬁlamentous phage progeny extrusion,
this barrier for antibiotic penetration may be less effective in
the bacterial cell.38 The second is the cell ﬁlamentation in the
presence of subinhibitory concentrations of b-lactams. This
was explained by the fact that these antibiotics, although
exhibiting different mechanisms of action, ﬁnally block bacte-
rial cell division.35,36 According to Comeau et al.37 phage
antibiotic synergism is a result of a change in morphology that
permits faster assembly of phages through altered or larger
pools of precursors important to phage maturation and accel-
erates the timing of cell lysis.
The results of this study demonstrated that the combination
of amikacin and the corresponding phage at MOI = 1 on the
P. aeruginosa bioﬁlm state was synergistic on 7 (50%) strains
with complete bioﬁlm eradication whereas 7 (50%) showed
no eradication. On the other hand, the combination of mero-
penem and the corresponding phage at MOI = one on the
P. aeruginosa bioﬁlm state showed synergistic effect in two
(14.28%) strains with complete bioﬁlm eradication, whereas
13 (85.7%) strains showed no bioﬁlm eradication.
Statistical analysis of the current results demonstrated that
the amikacin-phage combination caused statistically signiﬁ-
cant eradication (p= 0.003) of P. aeruginosa bioﬁlm, whereas
the meropenem-phage combination caused no signiﬁcant erad-
ication (p= 0.481) of P. aeruginosa bioﬁlm.
This effectiveness of combined treatment of phages and
amikacin on P. aeruginosa bioﬁlm can be explained by several
factors, namely altered surface charges of phage resistant phe-
notypes and disruption of the bioﬁlm matrix induced by some
of the phages which can enhance the antibiotic penetration.37
The results our study were similar to those of Fothergill
et al.38 They found that ciproﬂoxacin and norﬂoxacin caused
a level of phage induction higher than that observed with other
antibiotics (including meropenem) against the Liverpool epi-
demic strain of P. aeruginosa in the United Kingdom. Their
data suggest that the choice of antibiotic could dramatically
affect the levels of free Pseudomonas phages. P. aeruginosa
phage mobilization has been associated with increased diversi-
ﬁcation and the transduction of antibiotic resistance.
Bowler et al.39 reported that meropenem exposure stimu-
lated signiﬁcantly more b-lactamase production in mature bio-
ﬁlm and there was decreased b-lactamase production by all
planktonic bacteria exposed to meropenem after 24 h.
However, Sillankorva et al.33 observed antagonism with the
amikacin-phage combination to control P. aeruginosa
bioﬁlms.33 This antagonism could be explained as Kaplan40 sta-
ted in his study that P. aeruginosa bioﬁlm induction in response
to tobramycin is a speciﬁc response to aminoglycoside antibi-
otics rather than a non-speciﬁc response to translation inhibi-
tion or other cell stressors. It was found that mutants carried
transposon insertions in a gene designated arr, stands foraminoglycoside response regulator. The arr gene encodes a c-
di-GMP phosphodiesterase that degrades c-di-GMP and
reduces intracellular c-di-GMP concentrations. In which
reduced c-di-GMP levels induce P. aeruginosa bioﬁlm
formation.
In Conclusion, the amikacin-phage combination could have
potentially more beneﬁts on P. aeruginosa bioﬁlms than using
phages or antibiotics alone. Meropenem is not recommended
for non-growing bacteria in bioﬁlm. Combination of phage
and sub inhibitory concentrations of amikacin/meropenem
results in avoidance of antibiotic side effects occurring after
administration of high doses. It may be possible to commer-
cialize phage-based products containing a combination of bac-
teriophages, further studies are needed to use these phage
cocktails as phage therapy.
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